Install
Stay informed on the latest biopharmaceutical news, trends, and developments in Asia Pacific with BioPharma APAC. BioPharma Asia ( APAC ) provides in-depth analysis, insights, and expert commentary on drug development, regulatory updates, and industry partnerships in the region.
- 301articles · 90d
- 2+ day agolatest article
- Jun 15, 2026earliest in window
- 93%with images
- 274avg words
- Medical 185
- Health & Wellness 156
- Business & Industrial 121
- Economy, Business & Finance 121
- Health 93
- Science & Technology 81
- Science & Nature 63
- Finance & Business 32
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Forlong Biotechnology Completes Pivotal FL115 Manufacturing Milestone Ahead of Phase III NMIBC Trial
1+ mon, 1+ week ago (134+ words) 06 August 2026 | Thursday | News Forlong Biotechnology, a clinical-stage biotech company focused on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its manufacturing partner, JOINN Biologics, has successfully completed production of the FL115 pivotal batch, which will support…...
Thermo Fisher Launches Real-World Registry to Advance Long-Term Vitiligo Research
1+ mon, 1+ week ago (221+ words) 31 July 2026 | Friday | News Thermo Fisher Scientific, the world leader in serving science, announced the launch of the PPD™ CorEvitas™ Vitiligo Registry, a prospective, observational clinical registry designed to generate longitudinal real-world evidence in adolescents and adults living with nonsegmental vitiligo…...
Ractigen Therapeutics Raises Over $31 Million to Advance saRNA Drug Pipeline
1+ mon, 1+ week ago (115+ words) 31 July 2026 | Friday | News Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, tannounced the successful closing of a new financing round exceeding $31 million (over RMB 200 million). Clinical & Commercial Momentum Reflecting the global…...
Harbour BioMed and Sinopharm Form Strategic Alliance to Accelerate Innovative Biologics
1+ mon, 1+ week ago (593+ words) BioPharma APAC - Harbour BioMed and Sinopharm Form Strategic Alliance to Accelerate Innovative Biologics 29 July 2026 | Wednesday | News Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, announced…...
Waters Launches Next-Generation IVD Mass Spectrometer for High-Sensitivity Clinical Diagnostics
1+ mon, 1+ week ago (96+ words) 29 July 2026 | Wednesday | News Featuring the new StepWave™ XR Ion Guide, the Xevo TQ Absolute XR IVD System delivers improved robustness, enabling ion ratio consistency for up to six times longer compared with the Xevo TQ Absolute IVD System.4 This advancement…...
Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials for Solid Tumours
1+ mon, 2+ week ago (508+ words) BioPharma APAC - Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials for Solid Tumours 29 July 2026 | Wednesday | News Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug…...
AsymBio Breaks Ground on Shanghai R&D Hub to Accelerate Biologics Development
1+ mon, 2+ week ago (94+ words) 29 July 2026 | Wednesday | News Located within AsymBio's Fengxian site, adjacent to the clinical and commercial manufacturing facilities for antibodies and antibody-drug conjugates (ADCs), the building will serve as a dedicated R&D hub. Once operational, it will work in close alignment…...
Harbour BioMed Forecasts Record H1 2026 Profit as Strategic Partnerships Drive Growth
1+ mon, 2+ week ago (240+ words) 27 July 2026 | Monday | Company results Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, announced a positive profit alert for the six months ended June…...
Nova Biomedical Expands Cell Line Development Portfolio with NanoCellect Technology Acquisition
1+ mon, 2+ week ago (115+ words) 27 July 2026 | Monday | News Nova Biomedical announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expansion of Nova's portfolio will accelerate cell line development timelines and improve clone selection outcomes, while establishing a stronger…...
Nona Biosciences Partners with MedUni Vienna to Advance Fully Human Antibody Research
1+ mon, 2+ week ago (87+ words) 24 July 2026 | Friday | News Under the agreement, MedUni Vienna is granted the right to use Nona's technology for antibody generation and to further develop the resulting antibodies and antibody products for research, diagnostic, and therapeutic applications. The H2L2 Harbour Mice® platform and…...